Gene Therapy(FT-003) for Wet AMD
Phase 1
Recruiting
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- Genetic: FT-003
- First Posted Date
- 2024-07-09
- Last Posted Date
- 2024-07-09
- Lead Sponsor
- Frontera Therapeutics
- Target Recruit Count
- 78
- Registration Number
- NCT06492863
- Locations
- 🇨🇳
Tianjin Medical University Eye Hospital, Tianjin, Tianjin,China, China
Gene Therapy for DME
Phase 1
Recruiting
- Conditions
- Diabetic Macular Edema
- Interventions
- Genetic: FT-003
- First Posted Date
- 2024-07-09
- Last Posted Date
- 2024-07-09
- Lead Sponsor
- Frontera Therapeutics
- Target Recruit Count
- 78
- Registration Number
- NCT06492876
- Locations
- 🇨🇳
Tianjin Medical University Eye Hospital, Tianjin, Tianjin,China, China
Gene Therapy for RPGR Gene Mutation-associated X-linked Retinitis Pigmentosa
Phase 1
Recruiting
- Conditions
- X-Linked Retinitis Pigmentosa (XLRP)
- Interventions
- Genetic: FT-002
- First Posted Date
- 2024-07-09
- Last Posted Date
- 2024-07-09
- Lead Sponsor
- Frontera Therapeutics
- Target Recruit Count
- 32
- Registration Number
- NCT06492850
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
Gene Therapy for Diabetic Macular Edema
Phase 1
Recruiting
- Conditions
- Diabetic Macular Edema
- Interventions
- Genetic: FT-003
- First Posted Date
- 2023-06-23
- Last Posted Date
- 2023-06-23
- Lead Sponsor
- Frontera Therapeutics
- Target Recruit Count
- 18
- Registration Number
- NCT05916391
- Locations
- 🇨🇳
Tianjin Medical University Eye Hospital, Tianjin, Tianjin,China, China
Gene Therapy for Subjects With RPGR Mutation-associated X-linked Retinitis Pigmentosa
Early Phase 1
Recruiting
- Conditions
- X-Linked Retinitis Pigmentosa
- Interventions
- Genetic: FT-002
- First Posted Date
- 2023-05-24
- Last Posted Date
- 2023-05-24
- Lead Sponsor
- Frontera Therapeutics
- Target Recruit Count
- 18
- Registration Number
- NCT05874310
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
🇨🇳Eye & ENT hospital of Fudan university, Shanghai, Shanghai, China
Gene Therapy in Subjects With Biallelic RPE65 Mutation-associated Retinal Dystrophy
Phase 1
Recruiting
- Conditions
- Biallelic RPE65 Mutation-associated Retinal Dystrophy
- Interventions
- Genetic: FT-001 High DoseGenetic: FT-001 Mid DoseGenetic: FT-001 Low Dose
- First Posted Date
- 2023-05-15
- Last Posted Date
- 2023-05-15
- Lead Sponsor
- Frontera Therapeutics
- Target Recruit Count
- 9
- Registration Number
- NCT05858983
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
Gene Therapy for Wet AMD
Phase 1
Not yet recruiting
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- Genetic: FT-003
- First Posted Date
- 2022-11-10
- Last Posted Date
- 2023-04-26
- Lead Sponsor
- Frontera Therapeutics
- Target Recruit Count
- 18
- Registration Number
- NCT05611424
© Copyright 2025. All Rights Reserved by MedPath